Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
IMNN stock surged 158% following Phase 2 study results release. IMNN-001 showed 11.1-month increased median overall survival over standard treatment. A hazard ratio of 0.74 indicates 35% improvement in survival for IMNN-001. FDA plans meeting for Phase 3 study protocol anticipated in Q1 2025. Trial participants on PARP inhibitors had even better survival rates with IMNN-001.
- IMNN stock surged 158% following Phase 2 study results release.
- IMNN-001 showed 11.1-month increased median overall survival over standard treatment.
- A hazard ratio of 0.74 indicates 35% improvement in survival for IMNN-001.
- FDA plans meeting for Phase 3 study protocol anticipated in Q1 2025.
- Trial participants on PARP inhibitors had even better survival rates with IMNN-001.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.